Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring

Rapid Novor Inc., a global leader in mass spectrometry (MS)-based antibody protein sequencing, today announced that the first patient has been enrolled in a new clinical study titled 'Clinical evaluation of EasyM for disease response analysis in newly diagnosed MM patients (NDMM)'. In collaboration with Princess Margaret Cancer Centre (PMCC), and funding provided by Janssen Inc., a Johnson & Johnson company (J&J) , Rapid Novor is sponsoring the study to evaluate the clinical utility of its highly sensitive, non-invasive, clonotypic, mass spectrometry-based minimal residual disease (MRD) blood test, EasyM™ for MM.

Rapid novor teams up with pmcc to evaluate easym™ for multiple myeloma minimal residual disease monitoring
A clinical lab technician analyzing EasyM samples on mass spectrometer. Image Credit: Rapid Novor, Inc.

Multiple myeloma is the second most common form of hematological (blood) cancer with over 175,000 new cases diagnosed each year worldwide. The detection of MRD in patients with MM serves as one of the most powerful prognostic factors for progression-free and overall survival.

"We are excited to be working with PMCC and J&J for this prospective study for EasyM" states Dr. Liqiang Yang, Chief Strategy Officer at Rapid Novor. "This clinical study will help to accelerate the development and validation of our pioneering non-invasive MRD-disease monitoring technology for MM patients, with the aim to expand patient accessibility for enhanced disease monitoring and care."

The EasyM assay measures the levels of M-protein, a well-known biomarker for MM, in the patient's peripheral blood using Rapid Novor's proprietary MS-based protein sequencing technology.

EasyM's non-invasive nature represents a significant leap forward for MM monitoringBeing a simple, and extremely sensitive blood test, EasyMwill offer patients a more convenient alternative to highly invasive bone marrow biopsies."

Dr. Liqiang Yang, Chief Strategy Officer, Rapid Novor

Rapid Novor became a resident company in Johnson & Johnson Innovation, JLABS @ Toronto in 2018 and JLABS @ Shanghai in 2021. JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including the biotech and medical technology sectors.

In January 2023, Rapid Novor's diagnostic laboratory obtained its Clinical Laboratory Improvement Amendments (CLIA) certification, enabling patients with multiple myeloma to utilize EasyM as a clinical testing option.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Rapid Novor Inc. (2024, May 16). Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring. News-Medical. Retrieved on June 16, 2024 from https://www.news-medical.net/news/20240516/Rapid-Novor-teams-up-with-PMCC-to-evaluate-EasyMe284a2-for-multiple-myeloma-minimal-residual-disease-monitoring.aspx.

  • MLA

    Rapid Novor Inc. "Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring". News-Medical. 16 June 2024. <https://www.news-medical.net/news/20240516/Rapid-Novor-teams-up-with-PMCC-to-evaluate-EasyMe284a2-for-multiple-myeloma-minimal-residual-disease-monitoring.aspx>.

  • Chicago

    Rapid Novor Inc. "Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring". News-Medical. https://www.news-medical.net/news/20240516/Rapid-Novor-teams-up-with-PMCC-to-evaluate-EasyMe284a2-for-multiple-myeloma-minimal-residual-disease-monitoring.aspx. (accessed June 16, 2024).

  • Harvard

    Rapid Novor Inc. 2024. Rapid Novor teams up with PMCC to evaluate EasyM™ for multiple myeloma minimal residual disease monitoring. News-Medical, viewed 16 June 2024, https://www.news-medical.net/news/20240516/Rapid-Novor-teams-up-with-PMCC-to-evaluate-EasyMe284a2-for-multiple-myeloma-minimal-residual-disease-monitoring.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery